The estimated half-life and clearance of subcutaneous CT-P13 is comparable to findings from previous studies of intravenous infliximab in IBD, albeit with non-matched disease activity, weight, albumin and immunomodulator use between the models [49,50]. The gene discussed is ALB; the disease is inflammatory bowel disease.